Huntington disease: Implications for practice

Nurse Practitioner

Volumn 36, Issue 2, 2011, Pages 41-47

  Cummins, Angela ^a   Eggert, Julia ^b   Pruitt, Rosanne ^c   Collins, Julianne S ^d  

^a Wellsprings Medical Center   (United States)

^b CLEMSON UNIVERSITY   (United States)

^c Ball State Universty   (United States)

^d GREENWOOD GENETIC CENTER   (United States)

Author keywords

Chorea; Htt; Huntingtin; Huntington disease; Neurodegenerative disease

Indexed keywords

HUMAN; HUNTINGTON CHOREA; PATHOPHYSIOLOGY; REVIEW;

HUMANS; HUNTINGTON DISEASE;

EID: 79956218520     PISSN: 03611817     EISSN: 15388662     Source Type: Journal    
DOI: 10.1097/01.NPR.0000392796.01760.e2     Document Type: Article

References (37)

1. Huntington G. On chorea. Med Surg Rep. 1872;26:317-321.
2. Huntington's Outreach Project for Education, at Stanford (HOPES). 2009.
3. Aubeeluck A, Wilson E. Huntington's disease. Part 1: essential background and management. Br J Nurs. 2008;17(3):146-151.
4. Warby S, Graham R, Hayden M. Huntington disease. GeneReviews. 2007.
5. Harper B. Huntington disease. J R Soc Med. 2005;98(12):550.
6. Travers E, Jones K, Nichol J. Palliative care provision in Huntington's disease. Int J Palliat Nurs. 2007;13(3):125-130.
7. Pakenham KI, Goodwin VA, MacMillan JC. Adaptation for being at-risk for Huntington's disease and the availability of genetic testing: application of a stress and coping model. Psychol, Health, Med. 2004;9(3):380-397.
8. Gusella JF, Wexler NS, Conneally PM, et al. A polymorphic DNA marker genetically linked to Huntington's disease. Nature. 1983;306(5940):234-238.
9. Gusella JF, MacDonald ME, Ambrose CM, Duyao MP. Molecular genetics of Huntington's disease. Arch Neurol. 1993;50(11):1157-1163.
10. Truant R, Atweal R, Burtnik A. Hypothesis: huntingtin may function in membrane association and vesicular trafficking. Biochem Cell Biol. 2006;84(6):912-917.
11. Semaka K, Creighton S, Warby S, Hayden MR. Predictive testing for Huntington disease: interpretation and significance of intermediate alleles. Clin Genet. 2006;70(4):283-294.
12. Cowen CM, Raymond LA. Selective neuronal degeneration in Huntington's disease. Curr Top Dev Biol. 2006;75:25-71.
13. Van Raamsdonk JM, Murphy Z, Slow EJ, Leavitt BR, Hayden MR. Selective degeneration and nuclear localization of mutant huntingtin in YAC 128 mouse model of Huntington disease. Hum Mol Genet. 2005;14(24):3823-3835.
14. Duff K, Paulsen JS, Beglinger LJ, Langbehn DR, Stout JC, Predict-HD Investigators of the Huntington Study Group. Psychiatric symptoms in Huntington's disease before diagnosis: the Predict-HD Study. Biol Psychiatry. 2007;62(12):1341-1346.
15. Bonelli RM, Hofmann P. A review of the treatment options for Huntington's disease. Expert Opin Pharmacother. 2004;5(4):767-776.
16. Leegwater K, Cha J. The paradigm of Huntington's disease: therapeutic opportunities in neurodegeneration. NeuroRX. 2004;1(1):128-138.
17. Woodman B, Butler R, Landles C, et al. The Hdh(Q150/Q150) knock-in mouse model of HD and the R6/2 exon 1 model develop comparable and widespread molecular phenotypes. Brain Res Bull. 2007;72(2-3):83-97.
18. Calingasan NY, Ho DJ, Willie EJ, et al. Influence of mitochondrial enzyme deficiency on adult neurogenesis in mouse models of neurodegenerative diseases. Neuroscience. 2008;153(4):986-996.
19. Gong B, Lim MC, Wanderer J, Wyttenbach A, Morton AJ. Time-lapse analysis of aggregate formation in an inducible PC12 cell model of Huntington's disease reveals time-dependent aggregate formation that transiently delays cell death. Brain Res Bull. 2008;75(1):146-157.
20. Walker F. Huntington disease. Lancet. 2007;369:218-228.
21. Leontini R. Looking forward, looking back: the narrative of testing positive to Huntington's disease. Health Sociology Rev. 2006;15(2):144-155.
22. Aoun S, Kristjanson L, Oldham L. The challenges and unmet needs of people with neurodegenerative conditions and their careers. J Commun Nurses. 2006;11(1):17-20.
23. Zinzi P, Salmaso D, Gradis R, et al. Effects of an intensive rehabilitation programme on patients with Huntington's disease: a pilot study. Clin Rehab. 2007;21(7):603-613.
24. Timman R, Claus H, Slingerland H, et al. Nature and development of Huntington disease in a nursing home population: the Behavior Observation Scale Huntington (BOSH). Cogn Behav Neurol. 2005;18(4):215-222.
25. Huntington Study Group. Unified Huntington's disease rating scale: reliability and consistency. Mov Disord. 1996;11(2):136-142.
26. Simpson SA. Late stage care in Huntington's disease. Brain Res Bull. 2007;72(2-3):179-181.
27. Paulsen JS, Hoth KF, Nehl C, Stierman L. Critical periods of suicide risk in Huntington's disease. Am J Psychiatry. 2005;162(4):725-731.
28. Imbriglio S, Goolkasian V, Murfitt A. The family guide series: long term care. Huntington's Disease Society of America (HDSA). 2001.
29. Bourne C, Clayton C, Murch A, Grant J. Cognitive impairment and behavioral difficulties in patients with Huntington's disease. Nurs Stand. 2006;20(35):41-44
30. Imbriglio S. Physical and occupational therapy for Huntington's disease. Huntington's Disease Society of America (HDSA). 2003.
31. Aziz NA, van der Burg JMM, Landwehrmeyer GB, et al. Weight loss in Huntington disease increases with higher CAG repeat number. Neurology. 2008;71(19):1506-1513.
32. Rhodes L. Coping with speech and swallowing difficulties in Huntington's disease. Huntington's Disease Society of America (HDSA). 2003.
33. Gaba A. Nutrition and Huntington's disease. Huntington's Disease Society of America (HDSA). 2003.
34. Huntington Disease Index. Huntington disease medications. 2008.
35. Edmunds M & Mayhew M. Pharmacolgy for the Primary Care Provider. 2nd ed. Philadelphia: Elsevier Mosby; 2004:505-506,537-543,545-554,562-566.
36. . Tetrabenazine. .
37. Saft C, Lauter T, Kraus P, Horst P, Andrich JE. Dose-dependent improvement of myoclonic hyperkinesia due to Valproic acid in eight Huntington's disease patients: a case series. BMC Neurol. 2006;6:11.